Last reviewed · How we verify
curcuma longa
At a glance
| Generic name | curcuma longa |
|---|---|
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Assessment of Curcuma Longa Potentials for Soft and Hard Tissue Healing in Fresh (PHASE1)
- Effectiveness and Safety of Benemix® in Constipation (NA)
- The Effectiveness of a Herbal Supplement in Osteoarthritis. (NA)
- Flexy3 Supplementation and Joint Health (NA)
- Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory and Cardiovascular Biomarkers in Healthy, Older Individuals. (NA)
- Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum (NA)
- Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI (NA)
- ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- curcuma longa CI brief — competitive landscape report
- curcuma longa updates RSS · CI watch RSS
- Institut National de la Santé Et de la Recherche Médicale, France portfolio CI